215 related articles for article (PubMed ID: 22002346)
1. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
Andrews PA; Emery VC; Newstead C
Transplantation; 2011 Dec; 92(11):1181-7. PubMed ID: 22002346
[TBL] [Abstract][Full Text] [Related]
2. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
4. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines.
Le Page AK; Jager MM; Kotton CN; Simoons-Smit A; Rawlinson WD
Transplantation; 2013 Jun; 95(12):1455-60. PubMed ID: 23640298
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Manuel O; Perrottet N; Pascual M
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
7. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
Baillie GM
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
14. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
15. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
16. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
17. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
Reischig T
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
Razonable RR; Humar A
Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
[TBL] [Abstract][Full Text] [Related]
19. Management of cytomegalovirus infection in solid organ transplantation.
Kotton CN
Nat Rev Nephrol; 2010 Dec; 6(12):711-21. PubMed ID: 20978468
[TBL] [Abstract][Full Text] [Related]
20. Management of CMV infection and disease in transplant patients. 27-29 February 2004.
Razonable RR; Emery VC;
Herpes; 2004 Dec; 11(3):77-86. PubMed ID: 15960905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
